Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A Single Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally-Advanced Non-small Cell Lung Cancer (NSCLC)

Dan Levy Faber
* ORCID logo ,
Abed Agbarya
* ORCID logo ,
Ben Caspy
,
Moshe Lapidot
,
Shoshana Keren Rosenberg
,
Sonia Shnair
,
Erez Sharoni
,
Ronen Galili
Version 1 : Received: 9 April 2024 / Approved: 9 April 2024 / Online: 9 April 2024 (14:16:17 CEST)

How to cite: Faber, D.L.; Agbarya, A.; Caspy, B.; Lapidot, M.; Rosenberg, S.K.; Shnair, S.; Sharoni, E.; Galili, R. A Single Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally-Advanced Non-small Cell Lung Cancer (NSCLC). Preprints 2024, 2024040680. https://doi.org/10.20944/preprints202404.0680.v1 Faber, D.L.; Agbarya, A.; Caspy, B.; Lapidot, M.; Rosenberg, S.K.; Shnair, S.; Sharoni, E.; Galili, R. A Single Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally-Advanced Non-small Cell Lung Cancer (NSCLC). Preprints 2024, 2024040680. https://doi.org/10.20944/preprints202404.0680.v1

Abstract

Non-Small Cell Lung Cancer (NSCLC) is the most common pulmonary malignancy, most frequently diagnosed at an advanced stage (III/IV). Patients in the Locally-Advanced Stage Subgroup (IIIA) are relatively few, yet compose of heterogenic phenotypes posing a diagnostic and treating challenge, leading to lack of clinical guidelines regarding the optimal standard of care. Several approaches exist, with a general agreement that a combined oncological and surgical modality approach is required. In this current retrospective descriptive study, operable Stage IIIA NSCLC patients who underwent surgery between 2013-2020 were evaluated on several aspects, including initial diagnosis, neoadjuvant regimens, outcomes of surgical intervention, overall survival at 2-years and 5-years following treatment. A total of 35 patients had neoadjuvant oncological treatment (mostly chemoradiation therapy) prior to surgery, out of which 28 patients were diagnosed with Stage IIIA NSCLC. In post-operative assessment of pathological staging, downstaging was reported in 20 patients, of which 7 (25%) cases were defined as complete pathological response. The 2-years overall survival rate was 65% and the 5-years overall survival rate was 60%. The main pattern of disease recurrence was distant metastasis.

Keywords

Locally advanced stage; Neoadjuvant treatment; Non-Small Cell Lung Cancer, surgery; chemoradiation therapy, immunotherapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.